Drug Profile
Uracil topical - VioQuest Pharmaceuticals
Alternative Names: XyfidLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Asymmetric Therapeutics LLC
- Developer Cahaba Pharmaceuticals
- Class Antineoplastics; Nitrogen mustard compounds; Pyrimidinones
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Erythrodysaesthesia
- Discontinued Dermatitis
Most Recent Events
- 02 Apr 2007 Phase-I trials in Erythrodysaesthesia in USA (Topical)